NASDAQ:IRMD

Iradimed (IRMD) Stock Price, News & Analysis

$41.76
+0.29 (+0.70%)
(As of 11:28 AM ET)
Today's Range
$41.33
$42.11
50-Day Range
$40.36
$45.48
52-Week Range
$36.12
$51.04
Volume
9,031 shs
Average Volume
51,199 shs
Market Capitalization
$528.68 million
P/E Ratio
30.71
Dividend Yield
1.44%
Price Target
$62.50

Iradimed MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
49.7% Upside
$62.50 Price Target
Short Interest
Healthy
1.31% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
0.44mentions of Iradimed in the last 14 days
Based on 14 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
23.74%
From $1.39 to $1.72 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

5.00 out of 5 stars

Medical Sector

29th out of 908 stocks

Surgical & Medical Instruments Industry

5th out of 97 stocks

IRMD stock logo

About Iradimed Stock (NASDAQ:IRMD)

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.

IRMD Stock Price History

IRMD Stock News Headlines

Iradimed (NASDAQ:IRMD) Rating Reiterated by Roth Capital
What is the 72-Hour Profit Surge?
One of the most overlooked opportunities in the stock market is the 72-Hour Profit Surge... A short period of time where we can bet on a stock that is ALREADY “winning.” Let me give you a perfect example of how the Surge worked with Ross Stores. Back on November 16th, a little move was made that sent their stock soaring… The next day, my system would have alerted me that Ross Stores had entered the 72-Hour Profit Surge…
Iradimed's (IRMD) "Buy" Rating Reaffirmed at Roth Mkm
IRMD Jul 2024 60.000 call
A new way to collect income from stocks
Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…
iRadimed Corp.
Should You Invest in IRadimed Corporation (IRMD)?
IRMD Mar 2024 45.000 put
IRMD Mar 2024 40.000 call
IRMD Feb 2024 44.520 call
IRadimed: Q4 Earnings Snapshot
iRadimed's Earnings Outlook
iRadimed Q4 2023 Earnings Preview
Lake Street Reaffirms Their Buy Rating on Iradimed (IRMD)
See More Headlines
Receive IRMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iradimed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/08/2024
Today
4/26/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:IRMD
Employees
148
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$62.50
High Stock Price Target
$65.00
Low Stock Price Target
$60.00
Potential Upside/Downside
+50.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$17.19 million
Pretax Margin
33.16%

Debt

Sales & Book Value

Annual Sales
$65.56 million
Cash Flow
$1.39 per share
Book Value
$5.66 per share

Miscellaneous

Free Float
7,269,000
Market Cap
$525.01 million
Optionable
Optionable
Beta
0.82
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Roger E. Susi (Age 71)
    Founder, Chairman, CEO & President
    Comp: $586.04k
  • Mr. John F. Glenn (Age 62)
    CFO & Corporate Secretary
    Comp: $411.79k
  • Mr. Randy Waddell
    Vice President of Worldwide Sales & Marketing
  • Mr. Steve Kachelmeyer
    Vice President of Regulatory Affairs & Quality Assurance
  • Mr. Lynn Neuhardt
    Vice President of Research & Development
  • Mr. Chris Williamson
    Executive Vice President of Continuous Improvement & Information Technology
  • Mr. Matt Garner
    Controller

IRMD Stock Analysis - Frequently Asked Questions

Should I buy or sell Iradimed stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iradimed in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IRMD shares.
View IRMD analyst ratings
or view top-rated stocks.

What is Iradimed's stock price target for 2024?

3 analysts have issued twelve-month price objectives for Iradimed's stock. Their IRMD share price targets range from $60.00 to $65.00. On average, they expect the company's stock price to reach $62.50 in the next year. This suggests a possible upside of 49.7% from the stock's current price.
View analysts price targets for IRMD
or view top-rated stocks among Wall Street analysts.

How have IRMD shares performed in 2024?

Iradimed's stock was trading at $47.47 at the beginning of 2024. Since then, IRMD shares have decreased by 12.0% and is now trading at $41.76.
View the best growth stocks for 2024 here
.

When is Iradimed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our IRMD earnings forecast
.

How can I listen to Iradimed's earnings call?

Iradimed will be holding an earnings conference call on Thursday, May 2nd at 11:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Iradimed's earnings last quarter?

Iradimed Corporation (NASDAQ:IRMD) posted its quarterly earnings results on Thursday, February, 8th. The medical equipment provider reported $0.36 earnings per share for the quarter, missing analysts' consensus estimates of $0.37 by $0.01. The medical equipment provider had revenue of $17.45 million for the quarter. Iradimed had a trailing twelve-month return on equity of 24.62% and a net margin of 26.22%.

How often does Iradimed pay dividends? What is the dividend yield for Iradimed?

Iradimed announced a -- dividend on Tuesday, December 12th. Investors of record on Friday, December 22nd will be given a dividend of $0.15 per share on Friday, January 12th. The ex-dividend date is Thursday, December 21st.
Read our dividend analysis for IRMD
.

Is Iradimed a good dividend stock?

Iradimed (NASDAQ:IRMD) pays an annual dividend of $0.60 per share and currently has a dividend yield of 1.41%. The dividend payout ratio is 44.12%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, IRMD will have a dividend payout ratio of 34.88% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for IRMD.

What ETF holds Iradimed's stock?

Ballast Small/Mid Cap ETF holds 30,184 shares of IRMD stock, representing 0.93% of its portfolio.

What guidance has Iradimed issued on next quarter's earnings?

Iradimed issued an update on its first quarter 2024 earnings guidance on Thursday, February, 8th. The company provided EPS guidance of 0.330-0.350 for the period, compared to the consensus estimate of 0.410. The company issued revenue guidance of $17.0 million-$17.3 million, compared to the consensus revenue estimate of $17.6 million.

What other stocks do shareholders of Iradimed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iradimed investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Alphabet (GOOG), Mastercard (MA), Micron Technology (MU), PayPal (PYPL), CRISPR Therapeutics (CRSP), IntriCon (IIN), QUALCOMM (QCOM) and Twitter (TWTR).

Who are Iradimed's major shareholders?

Iradimed's stock is owned by a variety of institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.39%), Bridge City Capital LLC (0.33%), Shaker Investments LLC OH (0.16%), Hennion & Walsh Asset Management Inc. (0.07%) and Denali Advisors LLC (0.05%). Insiders that own company stock include Anthony Vuoto, Christopher K Scott, James B Hawkins, Monty K Allen, Monty K Allen and Roger E Susi.
View institutional ownership trends
.

How do I buy shares of Iradimed?

Shares of IRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IRMD) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners